◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

ホーム全銘柄 › AZN · English version

AstraZeneca PLC (AZN)

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街(米国) · 最終更新: 2026-08-16

AstraZeneca PLC はバイオ医薬品会社で、処方薬の発見、開発、製造、商品化に注力しています。

自動翻訳

主要指標

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル(DCF)→

年次損益計算書

損益計算書TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
売上高合計$61.4B$58.7B$54.1B$45.8B$44.4B$37.4B$26.6B$24.4B$22.1B$22.5B$23.0B$24.7B$26.5B$25.8B$28.0B$33.6B$33.3B$32.8B$31.6B$29.6B$26.5B
売上総利益$50.2B$48.1B$43.9B$37.5B$32.0B$25.0B$21.3B$19.5B$17.2B$18.1B$18.9B$20.1B$20.7B$20.5B$22.6B$27.6B$26.9B$27.0B$25.0B$23.1B$20.9B
売上総利益率 %81.9%81.9%81.1%82.0%72.1%66.8%80.1%79.8%77.7%80.8%82.1%81.2%78.0%79.6%80.7%82.1%80.8%82.4%79.1%78.3%79.0%
営業利益(EBIT)$14.0B$13.7B$10.0B$8.2B$3.8B$1.1B$5.2B$2.9B$3.4B$3.7B$4.9B$4.1B$2.1B$3.7B$8.1B$12.8B$11.5B$11.5B$9.1B$8.1B$8.2B
営業利益率 %22.8%23.4%18.5%17.9%8.5%2.8%19.4%12.0%15.3%16.4%21.3%16.7%8.1%14.4%29.1%38.1%34.5%35.2%28.9%27.4%31.0%
当期純利益$10.4B$10.3B$7.0B$6.0B$3.3B$112M$3.2B$1.3B$2.2B$3.0B$3.5B$2.8B$1.2B$2.6B$6.2B$9.9B$8.1B$7.5B$6.1B$5.6B$6.0B
純利益率 %17.0%17.5%13.0%13.0%7.4%0.3%12.0%5.5%9.8%13.4%15.2%11.4%4.6%9.9%22.3%29.5%24.2%22.9%19.3%18.9%22.8%
EBITDA$19.8B$15.4B$13.4B$9.1B$5.1B$8.1B$6.7B$7.1B$6.6B$7.3B$7.0B$5.5B$8.3B$10.7B$15.4B$14.7B$13.9B$12.6B$9.9B$9.6B
1株当たり利益(EPS)$6.69$6.57$4.50$3.81$2.11$0.16$4.87$2.05$3.40$4.74$5.53$4.47$1.95$4.08$9.87$14.51$11.14$10.37$8.40$7.47$7.70
発行済株式数(百万株)1,562M1,563M1,562M1,560M714M656M650M634M634M633M632M632M627M632M684M723M725M726M749M785M

出典: 企業の公開資料(SEC)。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は AZN のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/AZN

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.